Dr. Sartor on the Implications of the Analysis of Sipuleucel-T in Prostate Cancer

Oliver Sartor, MD
Published: Monday, Jun 26, 2017



Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Due to this analysis, it is important for the patients who are candidates for sipuleucel-T to receive it early in their treatment course since that is where the best outcomes were seen, explains Sartor.

This could lead to the hypothesis that perhaps African-American patients are more responsive to immunotherapy across many different cancer types, but this needs to be proven, states Sartor.
 


Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the implications of the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

Due to this analysis, it is important for the patients who are candidates for sipuleucel-T to receive it early in their treatment course since that is where the best outcomes were seen, explains Sartor.

This could lead to the hypothesis that perhaps African-American patients are more responsive to immunotherapy across many different cancer types, but this needs to be proven, states Sartor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x